Literature DB >> 9359477

Increased hyaluronidase levels in breast tumor metastases.

P Bertrand1, N Girard, C Duval, J d'Anjou, C Chauzy, J F Ménard, B Delpech.   

Abstract

Hyaluronidase, a matrix-degrading enzyme, was assayed in extracts from breast primary tumors and regional metastases using a pool of human sera as a standard. Optimal activities of tumor extracts and serum were found for concentrations of 0.15-0.20 M NaCl in pH 3.8-4.0 buffer. In evaluating contamination by serum due to vascular proliferation, we expressed our results as the ratio of the entire activity (mU/l extract) on serum albumin content of tumors (g/l). Median (interquartile range) activities were 9.02 (6.04-14.34) for primary tumors and 37.36 (24.06-99.63) mU/g albumin for metastases. The difference was significant. Zymographic analysis showed that 3 bands of activity were detected which corresponded to 68, 53 and 49 kDa for tumoral hyaluronidase. The same pattern was observed for cellular extracts of breast cancer cell line CAL51, demonstrating that hyaluronidase detected in tumor extracts had mainly a cellular origin. Our results suggest that hyaluronidase may be involved in the metastatic process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359477     DOI: 10.1002/(sici)1097-0215(19971104)73:3<327::aid-ijc4>3.0.co;2-1

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer.

Authors:  Ki Young Choi; Gurusamy Saravanakumar; Jae Hyung Park; Kinam Park
Journal:  Colloids Surf B Biointerfaces       Date:  2011-10-20       Impact factor: 5.268

Review 2.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

3.  Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Authors:  Erika da Costa Prando; Luciane Regina Cavalli; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

4.  Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer.

Authors:  Jaehee Choi; Hyunjin Kim; Yongdoo Choi
Journal:  Quant Imaging Med Surg       Date:  2015-10

Review 5.  Proteoglycans: pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland.

Authors:  M Delehedde; M Lyon; N Sergeant; H Rahmoune; D G Fernig
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

6.  Hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in the accumulation of hyaluronan in endometrioid endometrial carcinoma.

Authors:  Timo K Nykopp; Kirsi Rilla; Markku I Tammi; Raija H Tammi; Reijo Sironen; Kirsi Hämäläinen; Veli-Matti Kosma; Seppo Heinonen; Maarit Anttila
Journal:  BMC Cancer       Date:  2010-09-27       Impact factor: 4.430

Review 7.  Hyalurondiase: both a tumor promoter and suppressor.

Authors:  Vinata B Lokeshwar; Marie G Selzer
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 8.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

9.  Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis.

Authors:  Jin-Xiang Tan; Xiao-Yi Wang; Xin-Liang Su; Hong-Yuan Li; Yuan Shi; Liang Wang; Guo-Sheng Ren
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

10.  Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content.

Authors:  Timo K Nykopp; Kirsi Rilla; Reijo Sironen; Markku I Tammi; Raija H Tammi; Kirsi Hämäläinen; Anna-Mari Heikkinen; Marja Komulainen; Veli-Matti Kosma; Maarit Anttila
Journal:  BMC Cancer       Date:  2009-05-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.